Showing results (671-680 of 727) with videos related to
Sort By:
Pageof 73
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.Nanoscale|April 7, 2012
Large-scale parallel arrays of silicon nanowires via block copolymer directed self-assemblyRichard A Farrell, Niall T Kinahan, Stefan Hansel, et al.The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerIbiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.Pageof 73